S W Fesik

发表

An approach for high-throughput structure determination of proteins by NMR spectroscopy

A Medek, R. Meadows, E. Olejniczak, 2000, Journal of biomolecular NMR.

Controlling the Caspases

S. Fesik, Yigong Shi, S W Fesik, 2001, Science.

Identification of novel inhibitors of urokinase via NMR-based screening.

Jean M. Severin, P. Hajduk, S. Fesik, 2000, Journal of medicinal chemistry.

Design of adenosine kinase inhibitors from the NMR-based screening of fragments.

Jean M. Severin, E A Kowaluk, P. Hajduk, 2000, Journal of medicinal chemistry.

NMR studies of molecular complexes as a tool in drug design.

S. Fesik, S W Fesik, 1991, Journal of medicinal chemistry.

Heteronuclear three-dimensional NMR spectroscopy of isotopically labelled biological macromolecules

S. Fesik, E. Zuiderweg, E R Zuiderweg, 1990, Quarterly Reviews of Biophysics.

NMR-based screening in drug discovery

P. Hajduk, R. Meadows, S. Fesik, 1999, Quarterly Reviews of Biophysics.

Equilibrium denaturation of recombinant human FK binding protein in urea.

D. Egan, T. Logan, T. Holzman, 1993, Biochemistry.

Evaluation of PMF scoring in docking weak ligands to the FK506 binding protein.

P. Hajduk, S. Fesik, Y. Martin, 1999, Journal of medicinal chemistry.

NMR and mutagenesis evidence for an I domain allosteric site that regulates lymphocyte function-associated antigen 1 ligand binding.

J. R. Huth, E. Olejniczak, S. Fesik, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Privileged molecules for protein binding identified from NMR-based screening.

P. Hajduk, S. Fesik, J. Praestgaard, 2000, Journal of medicinal chemistry.

NMR structure-based drug design

S. Fesik, S W Fesik, Stephen W. Fesik, 1993, Journal of biomolecular NMR.

14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation.

S R Datta, M E Greenberg, Alexander Y Katsov, 2000, Molecular cell.

NMR studies of [U-13C]cyclosporin A bound to cyclophilin: bound conformation and portions of cyclosporin involved in binding.

D. Egan, E. Olejniczak, T. Holzman, 1994, Biochemistry.

Renin inhibitors. Design and synthesis of a new class of conformationally restricted analogues of angiotensinogen.

S. Fesik, J. Greer, H. Sham, 1988, Journal of medicinal chemistry.

Changes in the NMR-derived motional parameters of the insulin receptor substrate 1 phosphotyrosine binding domain upon binding to an interleukin 4 receptor phosphopeptide.

E. Olejniczak, S. Fesik, M. Zhou, 1997, Biochemistry.

Novel inhibitors of Erm methyltransferases from NMR and parallel synthesis.

P. Hajduk, A. Petros, S. Fesik, 1999, Journal of medicinal chemistry.

RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors

S. Fesik, V. Giranda, J. Leverson, 2006, Oncogene.

High-throughput nuclear magnetic resonance-based screening.

P. Hajduk, S. Fesik, D. Marek, 1999, Journal of medicinal chemistry.

Backbone dynamics of the C-terminal domain of Escherichia coli topoisomerase I in the absence and presence of single-stranded DNA.

S. Fesik, Y. Tse‐Dinh, L. Yu, 1996, Biochemistry.

Three-dimensional structure of the FK506 binding protein/ascomycin complex in solution by heteronuclear three- and four-dimensional NMR.

A. Petros, R. Meadows, E. Olejniczak, 1993, Biochemistry.

Novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. 2. Mechanism of inhibition and structure-based improvement of pharmaceutical properties.

E B Reilly, J. R. Huth, E. Olejniczak, 2001, Journal of medicinal chemistry.

Discovering High-Affinity Ligands for Proteins

P. Hajduk, R. Meadows, S. Fesik, 1997, Science.

Isotope-edited NMR of cyclosporin A bound to cyclophilin: evidence for a trans 9,10 amide bond.

D. Egan, T. Holzman, R. Simmer, 1990, Science.